The use of proteasome inhibitors in anti-cancer therapy

Marzena Teresa Baran, Paulina Miziak, Katarzyna Bonio



Proteins are the basic building blocks of the human body. Most proteins, after fulfilling their function, are degraded with the help of a multi-catalytic proteolytic complex - the 26S proteasome, thanks to its prior labeling with a poly-ubiquitin chain. The ubiquitin-proteasome complex is involved in the control of many important cellular processes. It is involved in the cell cycle, cell proliferation and growth, apoptosis, control of receptor function, quality of proteins in the endoplasmic reticulum, immune response, stress response and other extracellular factors. The dysfunction of the ubiquitin-proteasome pathway plays an important role in the development of many neurodegenerative and neoplastic diseases, as well as diseases with an immune and infectious origin. Accordingly, research is being conducted where the UPS complex is the target of therapeutic activities. Specific proteasome inhibitors are used in cancer therapy. The first to be approved by the FDA was bortezomib, which is a peptide derivative of boric acid. It has the ability to initiate the process of apoptosis by inhibiting the activity of the NF-κB protein, which is a transcription factor. This compound is used in the treatment of multiple myeloma and malignant lung and breast cancers. There are also studies on the combination of proteasome inhibitors with other chemotherapeuticam. There is still growing interest in research aimed at obtaining substances that allowed to control the mechanisms of proteolytic degradation.


Ubiquitin; proteasome; proteasome inhibitors; anti-cancer therapy

Full Text:



Podgórska J., Komórkowy system sprzątający – degradacja proteasomalna i jej rola w terapii onkologicznej,, 2017

M. Staszczak (2017), Szalak ubikwityna- proteasom, jako cel strategii terapeutycznych, Postępy Biochemii 53 (4), 289-291

Bubko I. i inni, Rola proteasomu w terapii chorób nieuleczalnych, Postepy Hig Med Dosw., 2010; 64: 314-325

Maliński M., Cichocki M., Inhibicja aktywności proteasomu, jako nowa strategia w terapii i chemioprewencji nowotworów, Postepy Hig Med Dosw 2013; 67 : 90-106

N. M. Weathington, R. K. Mallampalli (2014), Emerging therapies targeting the ubiquitin

proteasome system in cancer, The Journal of Clinical Investigation, 124,1

Dees E.C, Orlowski R.Z., 2006, Targeting the ubiquitin–proteasome pathway in breast cancer therapy, Future Oncol. (2006) 2(1), 122

Kazula A., Kazula E., Proteasomy a nowe kierunki terapii, Terapia i Leki., (2009)., tom 65, nr.7

Henshall F.N., Kumar S. T, Ubiquitination and the regulation of membrane proteins. Physiol. Rev. (2017). 97: 253-281

Stój J., Karpowicz P., Proteolityczny kombinat i jego regulatory, Wiadomości chemiczne, (2012), 66

Romaniuk R. i inni, Inhibitory proteasomów w terapii onkologicznej, Postepy Hig Med Dosw., (2015) 69: 1443-1450

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM

Journal of Education, Health and Sport formerly Journal of Health Sciences

Declaration on the original version.

Editors indicates that the main version of the magazine is to issue a "electronic".

The journal has had 5 points in Ministry of Science and Higher Education parametric evaluation. § 8. 2) and § 12. 1. 2) 22.02.2019.

1223 Journal of Education, Health and Sport eISSN 2391-8306 7

ISSN 2391-8306 formerly ISSN: 1429-9623 / 2300-665X

Archives 2011 - 2014

PBN 2011 - 2014

POL-index 2011 - 2014

BASE 2011 - 2014

Indexed in Bases, Bazy indeksacyjne: ERIH Plus, Worldcat, PBN/POL-Index, ICI Journals Master List, Directory of Open Access Journals (DOAJ), ZBD, Ulrich's periodicals, Google Scholar, Polska Bibliografia Lekarska, EuroPub database, NLM Catalog Result - NCBI, BASE, Russian Sciences Index, Arianta.

US NLM = 101679844

101679844 - NLM Catalog Result - NCBI

Find a library that holds this journal:


PBN Poland



Redaction, Publisher and Editorial Office

Publisher and Editorial Office
Department of Physical Culture,
Faculty of Earth Sciences and Spatial Management,
Nicolaus Copernicus University in Toruń, Poland
Address: Str. Lwowska 1, 87-100 Toruń, Poland

  Open Access ISSN 2391-8306 formerly ISSN: 1429-9623 / 2300-665X

The journal has been approved for inclusion in ERIH PLUS.

The ERIH PLUS listing of the journal is available at

Indexed in Index Copernicus Journals Master List.,p24782242,3.html

ICV 2019 = 100.00 ICV 2018 = 95.95 ICV 2017 = 91.30 ICV 2016 = 84.69 ICV 2015 = 93.34 ICV 2014 = 89.51 Standardized Value: 8.27 ICV 2013: 7.32 ICV 2012: 6.41 ICV 20115.48

RG Journal Impact: 0.18 *

*This value is calculated using ResearchGate data and is based on average citation counts from work published in this journal. The data used in the calculation may not be exhaustive.

RG Journal impact history

2020Available summer 2021
2018 / 20190.18

RG Journal impact over time

RG Journal impact

Indexed in Polish Scholarly Bibliography (PBN) (PBN Polska Bibliografia Naukowa) (

is a portal of the Polish Ministry of Science and Higher Education, collecting information on publications of Polish scientists and on Polish and foreign scholarly journals. Polish Scholarly Bibliograhpy is a part of POL-on - System of Information on Higher Education. It is operated by the Interdisciplinary Centre for Mathematical and Computational Modelling, University of Warsaw.

Indexed in Russian Sciences Index Российский индекс научного цитирования (РИНЦ)

Indexed in Arianta Polish scientific and professional electronic journals Aneta Drabek i Arkadiusz Pulikowski


Partnerzy platformy czasopism